These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15980671)

  • 21. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
    Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
    Schiff ER; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann HL; Samuel D; Zeuzem S; Lilly L; Rendina M; Villeneuve JP; Lama N; James C; Wulfsohn MS; Namini H; Westland C; Xiong S; Choy GS; Van Doren S; Fry J; Brosgart CL;
    Hepatology; 2003 Dec; 38(6):1419-27. PubMed ID: 14647053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
    Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM
    J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B].
    Suárez E; Gila A; Figueruela B; Chueca N; Muñoz Rueda P; Puche B; Fraga E; García F; Martín JM; Andrade RJ; Nogales C; Romero-Gómez M; Salmerón J
    Gastroenterol Hepatol; 2011 Feb; 34(2):69-74. PubMed ID: 21334762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    Lv GC; Yao JM; Yang YD; Zheng L; Sheng JF; Chen Y; Li LJ
    World J Gastroenterol; 2013 Jun; 19(22):3481-6. PubMed ID: 23801842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
    Tillmann HL; Bock CT; Bleck JS; Rosenau J; Böker KH; Barg-Hock H; Becker T; Trautwein C; Klempnauer J; Flemming P; Manns MP
    Liver Transpl; 2003 Feb; 9(2):191-6. PubMed ID: 12548514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lamivudine and adefovir dipivoxil combination treatment for liver cirrhosis patients with CHB].
    Yang DH; Xie SF; Wang YM; Zhao NF; Li MW
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):473-4. PubMed ID: 18579006
    [No Abstract]   [Full Text] [Related]  

  • 30. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.
    Zoulim F; Parvaz P; Marcellin P; Zarski JP; Beaugrand M; Benhamou Y; Bailly F; Maynard M; Trepo C; Trylesinski A; Monchecourt F;
    Liver Int; 2009 Mar; 29(3):420-6. PubMed ID: 18795900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic hepatitis B--treatment with nucleoside analogues.
    Leung N
    Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of patients with decompensated HBV cirrhosis.
    Fontana RJ
    Semin Liver Dis; 2003 Feb; 23(1):89-100. PubMed ID: 12616454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.
    Woo HY; Choi JY; Yoon SK; Suh DJ; Paik SW; Han KH; Um SH; Kim BI; Lee HJ; Cho M; Lee CK; Kim DJ; Hwang JS
    Clin Mol Hepatol; 2014 Jun; 20(2):168-76. PubMed ID: 25032183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
    Jung HW; Choi MS; Kim KH; Park SH; Yeon KK; Lee JH; Koh KC; Paik SW; Yoo BC
    Korean J Hepatol; 2009 Mar; 15(1):52-8. PubMed ID: 19346785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.